Pharmaceutical market - All That Stats

- Variable
  - Total pharmaceutical consumption
    - 00 A-Alimentary tract and metabolism
    - 01 A02A-Antacids
    - 02 A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)
    - 03 A10-Drugs used in diabetes
    - 04 B-Blood and blood forming organs
    - 05 C-Cardiovascular system
    - 06 C01A-Cardiac glycosides
    - 07 C01B-Antiarrhythmics, Class I and III
    - 08 C02-Antihypertensives
    - 09 C03-Diuretics
    - 0a C07-Beta blocking agents
    - 0b C08-Calcium channel blockers
    - 0c C09-Agents acting on the Renin-Angiotensin system
    - 0d C10-Lipid modifying agents
    - 0e G-Genito urinary system and sex hormones
    - 0f G03-Sex hormones and modulators of the genital system
    - 0g H-Systemic hormonal preparations, excluding sex hormones and insulins
    - 0h J-Antiinfectives for systemic use
    - 0i J01-Antibacterials for systemic use
    - 0j M-Musculo-skeletal system
    - 0k M01A-Antiinflammatory and antirheumatic products non-steroids
    - 0l N-Nervous system
    - 0m N02-Analgesics
    - 0n N05B-Anxiolytics
    - 0o N05C-Hypnotics and sedatives
    - 0p N06A-Antidepressants
    - 0q R-Respiratory system
    - 0r R03-Drugs for obstructive airway diseases
  - Total pharmaceutical sales
    - 0s Total pharmaceutical sales
    - 0t A-Alimentary tract and metabolism
    - 0u A02A-Antacids
    - 0v A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)
    - 0w A10-Drugs used in diabetes
    - 0x B-Blood and blood forming organs
    - 0y C-Cardiovascular system
    - 0z C01A-Cardiac glycosides
    - 10 C01B-Antiarrhythmics, Class I and III
    - 11 C02-Antihypertensives
    - 12 C03-Diuretics
    - 13 C07-Beta blocking agents
    - 14 C08-Calcium channel blockers
    - 15 C09-Agents acting on the Renin-Angiotensin system
    - 16 C10-Lipid modifying agents
    - 17 G-Genito urinary system and sex hormones
    - 18 G03-Sex hormones and modulators of the genital system
    - 19 H-Systemic hormonal preparations, excluding sex hormones and insulins
    - 1a J-Antiinfectives for systemic use
    - 1b J01-Antibacterials for systemic use
    - 1c M-Musculo-skeletal system
    - 1d M01A-Antiinflammatory and antirheumatic products non-steroids
    - 1e N-Nervous system
    - 1f N02-Analgesics
    - 1g N05B-Anxiolytics
    - 1h N05C-Hypnotics and sedatives
    - 1i N06A-Antidepressants
    - 1j R-Respiratory system
    - 1k R03-Drugs for obstructive airway diseases
    - 1l Products not elsewhere classified
  - Generic market
    - 1m Total pharmaceutical market
    - 1n Third-party-payer market
    - 1o Community pharmacy market
    - 1p Hospital pharmaceutical market
- Measure
  - 0 Defined daily dosage per 1 000 inhabitants per day
  - 1 Million of national currency units
  - 2 Million US$ at exchange rate
  - 3 Million US$, purchasing power parity
  - 4 /capita, US$ exchange rate
  - 5 /capita, US$ purchasing power parity
  - 6 % of total sales
  - 7 % share of generics (value)
  - 8 % share of generics (volume)
- Country
  - 00 Australia
  - 01 Austria
  - 02 Belgium
  - 03 Canada
  - 04 Chile
  - 05 Costa Rica
  - 06 Czechia
  - 07 Denmark
  - 08 Estonia
  - 09 Finland
  - 0a France
  - 0b Germany
  - 0c Greece
  - 0d Hungary
  - 0e Iceland
  - 0f Ireland
  - 0g Israel
  - 0h Italy
  - 0i Japan
  - 0j Korea
  - 0k Latvia
  - 0l Lithuania
  - 0m Luxembourg
  - 0n Mexico
  - 0o Netherlands
  - 0p New Zealand
  - 0q Norway
  - 0r Poland
  - 0s Portugal
  - 0t Slovak Republic
  - 0u Slovenia
  - 0v Spain
  - 0w Sweden
  - 0x Switzerland
  - 0y Türkiye
  - 0z United Kingdom
  - Non-OECD Economies
    - 10 Bulgaria
    - 11 Croatia
    - 12 Romania
    - 13 Russia

Pharmaceutical market Methoden, Erläuterungen und Klassifizierung

Erläuterungen

Variables Download